Gilead Sciences (GILD) Tops Q4 EPS by 9c, Offers FY17 Guidance
Gilead Sciences (NASDAQ: GILD) reported Q4 EPS of $2.70, $0.09 better than the analyst estimate of $2.61. Revenue for the quarter came in at $7.3 billion versus the consensus estimate of $7.15 billion.
Full Year 2017 Guidance
Gilead provided its full year 2017 guidance:
| (In millions, except percentages and per share amounts) | Provided February 7, 2017 | |
| Net Product Sales | $22,500 - $24,500 | |
| Non-HCV Product Sales | $15,000 - $15,500 | |
| HCV Product Sales | $7,500 - $9,000 | |
| Non-GAAP* | ||
| Product Gross Margin | 86% - 88% | |
| R&D Expenses | $3,100 - $3,400 | |
| SG&A Expenses | $3,100 - $3,400 | |
| Effective Tax Rate | 25.0% - 28.0% | |
| Diluted EPS Impact of Acquisition-related, Up-front Collaboration, Stock-Based Compensation and Other Expenses | $0.84 - $0.91 |
For earnings history and earnings-related data on Gilead Sciences (GILD) click here.